What is the role of exogenous glucagonlike peptide 1 (GLP-1) in the treatment of type 1 diabetes mellitus (DM)?

Updated: Oct 08, 2021
  • Author: Romesh Khardori, MD, PhD, FACP; Chief Editor: George T Griffing, MD  more...
  • Print

Although patients with type 1 DM have normal incretin response to meals, administration of exogenous glucagonlike peptide 1 (GLP-1) reduces peak postprandial glucose by 45%. Long-term effects of exogenously administered GLP-1 analogues warrant further studies. [108]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!